Carbon ion radiation guided by scans for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 trial tests whether using detailed scans (PSMA PET/CT and MRI) to guide carbon ion radiation—delivered in a focused way—can treat localized prostate cancer. It may help target the treatment more precisely while avoiding areas that are not involved.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by pathology as adenocarcinoma
- Your prostate cancer is localized (cT1 to cT3) with no lymph node or distant spread
- Before starting, you must have had both PSMA PET/CT and prostate MRI scans
- You have never had radiation to the pelvis and you have not had prostate surgery (prostatectomy)
- You are between 45 and 84 years old, and your daily functioning score (Karnofsky) is at least 70
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special PET scan tracer (18F-DCFPyL) can show how well focused radiation (SBRT) is working for localized prostate cancer. It may help doctors spot treatment response earlier and tailor follow-up care.
This trial tests whether a special PET/MRI scan (using a tracer called 68Ga-PSMA-11) can better identify the main tumor in men with early prostate cancer who are planning surgery. The goal is to help doctors target treatment more precisely in the future.
This trial tests a type of radiation that uses carbon ions to treat pancreatic cancer that can’t be removed with surgery but has not spread to distant organs. It may help shrink or control the tumor while limiting radiation side effects to nearby organs.
This trial tests a short course of carbon ion radiation for prostate cancer. It aims to treat the cancer effectively while limiting side effects and shortening treatment time.
This trial tests a precise radiation technique that adapts to your body's daily changes. It may offer better outcomes for men with prostate cancer that hasn't spread outside the pelvic area.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
Hear when a new Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.